To develop an iPSC-derived CAR-T therapy for solid tumours, we recently generated CAR-expressing iPSC-derived NK/innate lymphocyte cells (ILCs) that target glypican3 (GPC3)-expressing tumours15, such as hepatocellular carcinoma and ovarian clear cell carcinoma. The gene discussed is GPC3; the disease is ovarian clear cell cancer.